Apraglutide
Also called FE 203799
Subcutaneous (under the skin)Human study reference
Research reference
Human study
Apraglutide metabolic-balance trial
5 mg once weekly
4 weeks
Apraglutide phase 1/2 trial (2022) ↗When results may show
- When change was measured
- Fluid, electrolyte and energy absorption were measured in metabolic-balance studies—not a general digestive-health timeline.
- When to assess
- 4 weeks
- Conditions and limitations
- Eight adults with short-bowel intestinal insufficiency or failure. A small specialist short-bowel experiment does not establish a universal gut-repair starter, maintenance course or support-reduction plan.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: Apraglutide phase 1/2 trial (2022)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Apraglutide describe 2.5–5 mg per administration. Descriptive only, not a recommendation.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 0.99× single dose
- Time to steady state
- 6.3days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Apraglutide phase 1/2 trial (2022)A small specialist short-bowel experiment does not establish a universal gut-repair starter, maintenance course or support-reduction plan.